Is Angelman Syndrome hereditary?

Angelman syndrome is a genetic condition, but it is rarely hereditary; in the vast majority of cases, it is caused by a sporadic, de novo genetic event that occurs for the first time in the affected individual. Because the condition typically arises from non-inherited mutations affecting the maternal copy of the UBE3A gene on chromosome 15, parents of a child with Angelman syndrome are generally at a very low risk of having another child with the condition.

Is Angelman syndrome considered a hereditary condition?

While Angelman syndrome is fundamentally a genetic disorder, it is usually not "hereditary" in the traditional sense, meaning it is not typically passed down from parent to child. The condition is caused by the loss of function of the UBE3A gene, which is located on chromosome 15. In a healthy individual, both the maternal and paternal copies of this gene are present, but only the maternal copy is active in certain areas of the brain. When that maternal copy is missing, damaged, or silenced, Angelman syndrome occurs. Because this usually happens due to a random error during egg or sperm formation or early embryonic development, most cases are de novo, meaning they are not inherited from the parents.

How does the inheritance of Angelman syndrome work?

Understanding how Angelman syndrome is inherited requires looking at the specific molecular mechanism involved. There are four primary genetic mechanisms that result in the syndrome:

• Deletion (approx. 70-75% of cases): A segment of the maternal chromosome 15 containing the UBE3A gene is missing. This is a sporadic event.


• Uniparental Disomy (approx. 3-7% of cases): The individual inherits two copies of chromosome 15 from the father and none from the mother.


• Imprinting defects (approx. 3-5% of cases): The maternal gene is present but is "switched off" due to an error in the imprinting process.


• UBE3A mutation (approx. 8-11% of cases): A mutation occurs within the maternal UBE3A gene itself, rendering it non-functional.

In rare instances, an imprinting defect or a UBE3A mutation can be inherited from an unaffected mother who carries the genetic predisposition, which is why clinical genetic evaluation is essential.

When is genetic testing recommended for Angelman syndrome?

Genetic testing is the gold standard for diagnosing Angelman syndrome and should be pursued if a child exhibits characteristic features such as developmental delay, speech impairment, movement or balance disorders, and a uniquely happy demeanor. Diagnostic testing usually begins with a methylation analysis, which can identify about 80% of cases. If the methylation test is normal but clinical suspicion remains high, further testing—such as UBE3A gene sequencing—is used to identify specific mutations.

What is the role of genetic counseling?

Genetic counseling is a vital step for families navigating an Angelman syndrome diagnosis. A counselor will perform a detailed family history to determine if the specific genetic mechanism identified in the patient could potentially recur in future pregnancies. For the 263 members of our DiseaseMaps.org community, counseling has provided clarity regarding recurrence risks, which are generally less than 1% for most mechanisms but can be as high as 50% if a mother carries a specific imprinting mutation. Genetic counselors also provide emotional support, helping families process the diagnosis and connect with resources.

Next steps

• Consult with a board-certified clinical geneticist to confirm the specific molecular mechanism of the Angelman syndrome diagnosis in your family.


• Request a referral for genetic counseling before planning future pregnancies to discuss recurrence risks and prenatal testing options.


• Connect with the DiseaseMaps.org community to share experiences and learn from others who have navigated the diagnostic journey.


• Visit the Angelman Syndrome Foundation to access the latest clinical trial information and support resources.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) Genetic and Rare Diseases Information Center (GARD).


• Orphanet: The portal for rare diseases and orphan drugs.


• Online Mendelian Inheritance in Man (OMIM): Entry #105830.


• Angelman Syndrome Foundation (ASF).